Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
Clinical Breast Cancer
|
December 18, 2013
Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study
Mark E Burkard, Kari B Wisinski, Uchenna O Njiaju, et al.
Cancer
|
June 17, 2015
A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study
Timothy S Fenske, Namrata M Shah, Kyung Mann Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 21, 2022
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline
W Kimryn Rathmell, R Bryan Rumble, Peter J Van Veldhuizen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 25, 2025
Circulating tumor cells dynamics after CDK4/6 inhibitor for hormone-receptor positive metastatic breast cancer: a biomarker analysis from the PACE phase II study
Lorenzo Gerratana, Carolina Reduzzi, Yue Ren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 28, 2013
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab
Lee S Schwartzberg, Kurt W Tauer, Robert C Hermann, et al.
JAMA Oncology
|
February 27, 2025
Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality: The ECOG-ACRIN EA9131 Trial
Anand P Jillella, Sandra J Lee, Jessica K Altman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 2024
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer
Erica L Mayer, Yue Ren, Nikhil Wagle, et al.
JCO Oncology Practice
|
April 28, 2026
Engendering Reproductive Health Within Oncologic Survivorship Trial, ECOG-ACRIN E1Q11
Ashlesha A Patel, Ju-Whei Lee, Howard A Zaren, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
Clinical Breast Cancer
|
December 18, 2013
Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study
Mark E Burkard, Kari B Wisinski, Uchenna O Njiaju, et al.
Cancer
|
June 17, 2015
A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study
Timothy S Fenske, Namrata M Shah, Kyung Mann Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 21, 2022
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline
W Kimryn Rathmell, R Bryan Rumble, Peter J Van Veldhuizen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 25, 2025
Circulating tumor cells dynamics after CDK4/6 inhibitor for hormone-receptor positive metastatic breast cancer: a biomarker analysis from the PACE phase II study
Lorenzo Gerratana, Carolina Reduzzi, Yue Ren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 28, 2013
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab
Lee S Schwartzberg, Kurt W Tauer, Robert C Hermann, et al.
JAMA Oncology
|
February 27, 2025
Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality: The ECOG-ACRIN EA9131 Trial
Anand P Jillella, Sandra J Lee, Jessica K Altman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 2024
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer
Erica L Mayer, Yue Ren, Nikhil Wagle, et al.
JCO Oncology Practice
|
April 28, 2026
Engendering Reproductive Health Within Oncologic Survivorship Trial, ECOG-ACRIN E1Q11
Ashlesha A Patel, Ju-Whei Lee, Howard A Zaren, et al.
Page
of 2